Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue

Background. The evaluation of tumour-infiltrating lymphocytes (TILs) in solid malignancies has yielded insights into immune regulation within the tumour microenvironment and has also led to the development and optimisation of adoptive T cell therapies. Objectives. This study examined the in vitro ex...

Full description

Saved in:
Bibliographic Details
Main Authors: Linh T. Nguyen, Charlotte S. Lo, Michael Fyrsta, Jessica Nie, Jennifer Y. Yam, Pei-Hua Yen, Michael X. Le, Karen Hersey, Miran Kenk, Megan Crumbaker, Neil Fleshner, Girish Kulkarni, Robert Hamilton, Michael Jewett, Antonio Finelli, Andrew Evans, Joan Sweet, Pamela S. Ohashi, Anthony M. Joshua
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Prostate Cancer
Online Access:http://dx.doi.org/10.1155/2022/6499344
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850178179043426304
author Linh T. Nguyen
Charlotte S. Lo
Michael Fyrsta
Jessica Nie
Jennifer Y. Yam
Pei-Hua Yen
Michael X. Le
Karen Hersey
Miran Kenk
Megan Crumbaker
Neil Fleshner
Girish Kulkarni
Robert Hamilton
Michael Jewett
Antonio Finelli
Andrew Evans
Joan Sweet
Pamela S. Ohashi
Anthony M. Joshua
author_facet Linh T. Nguyen
Charlotte S. Lo
Michael Fyrsta
Jessica Nie
Jennifer Y. Yam
Pei-Hua Yen
Michael X. Le
Karen Hersey
Miran Kenk
Megan Crumbaker
Neil Fleshner
Girish Kulkarni
Robert Hamilton
Michael Jewett
Antonio Finelli
Andrew Evans
Joan Sweet
Pamela S. Ohashi
Anthony M. Joshua
author_sort Linh T. Nguyen
collection DOAJ
description Background. The evaluation of tumour-infiltrating lymphocytes (TILs) in solid malignancies has yielded insights into immune regulation within the tumour microenvironment and has also led to the development and optimisation of adoptive T cell therapies. Objectives. This study examined the in vitro expansion of TILs from prostate adenocarcinoma, as a preliminary step to evaluate the potential of TILs for adoptive T cell therapy. Design, Setting, and Participants. Malignant and adjacent nonmalignant tissues were obtained from fifteen men undergoing radical prostatectomy. Interventions. There were no study interventions. Outcome Measurements and Statistical Analysis. Expanded cells were analysed by flow cytometry, and the data was assessed for associations between cell subpopulations and expansion rate. Results. Tumour-infiltrating lymphocytes could be expanded to numbers that would be needed to generate a therapeutic infusion product from nine of 15 malignant specimens (60%). The CD4+ T cells predominated over CD8+ T cells (median 56.8% CD4+, 30.0% CD8+), and furthermore, faster TIL expansion was associated with a higher proportion of CD4+ T cells (median 69.8% in faster-growing cultures; 36.8% in slower-growing cultures). A higher proportion of CD3−CD56+ cells versus CD3+ cells was associated with slower TIL expansion in cultures from malignant specimens (median 13.3% in slower-growing cultures versus 2.05% in faster-growing cultures), but not from nonmalignant specimens. Conclusions. The expansion of TILs for potential therapeutic use is feasible. Our findings also indicate that further examination of TILs from prostate adenocarcinomas may yield insights into mechanisms of regulation of T cells within the tumour microenvironment. Further research is required to evaluate their therapeutic potential.
format Article
id doaj-art-c4ca7626d4f24677b4e9214d25a6de45
institution OA Journals
issn 2090-312X
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Prostate Cancer
spelling doaj-art-c4ca7626d4f24677b4e9214d25a6de452025-08-20T02:18:47ZengWileyProstate Cancer2090-312X2022-01-01202210.1155/2022/6499344Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant TissueLinh T. Nguyen0Charlotte S. Lo1Michael Fyrsta2Jessica Nie3Jennifer Y. Yam4Pei-Hua Yen5Michael X. Le6Karen Hersey7Miran Kenk8Megan Crumbaker9Neil Fleshner10Girish Kulkarni11Robert Hamilton12Michael Jewett13Antonio Finelli14Andrew Evans15Joan Sweet16Pamela S. Ohashi17Anthony M. Joshua18Princess Margaret Cancer CentrePrincess Margaret Cancer CentrePrincess Margaret Cancer CentrePrincess Margaret Cancer CentrePrincess Margaret Cancer CentrePrincess Margaret Cancer CentrePrincess Margaret Cancer CentrePrincess Margaret Cancer CentrePrincess Margaret Cancer CentreKinghorn Cancer CentrePrincess Margaret Cancer CentrePrincess Margaret Cancer CentrePrincess Margaret Cancer CentrePrincess Margaret Cancer CentrePrincess Margaret Cancer CentreMackenzie HealthPrincess Margaret Cancer CentrePrincess Margaret Cancer CentrePrincess Margaret Cancer CentreBackground. The evaluation of tumour-infiltrating lymphocytes (TILs) in solid malignancies has yielded insights into immune regulation within the tumour microenvironment and has also led to the development and optimisation of adoptive T cell therapies. Objectives. This study examined the in vitro expansion of TILs from prostate adenocarcinoma, as a preliminary step to evaluate the potential of TILs for adoptive T cell therapy. Design, Setting, and Participants. Malignant and adjacent nonmalignant tissues were obtained from fifteen men undergoing radical prostatectomy. Interventions. There were no study interventions. Outcome Measurements and Statistical Analysis. Expanded cells were analysed by flow cytometry, and the data was assessed for associations between cell subpopulations and expansion rate. Results. Tumour-infiltrating lymphocytes could be expanded to numbers that would be needed to generate a therapeutic infusion product from nine of 15 malignant specimens (60%). The CD4+ T cells predominated over CD8+ T cells (median 56.8% CD4+, 30.0% CD8+), and furthermore, faster TIL expansion was associated with a higher proportion of CD4+ T cells (median 69.8% in faster-growing cultures; 36.8% in slower-growing cultures). A higher proportion of CD3−CD56+ cells versus CD3+ cells was associated with slower TIL expansion in cultures from malignant specimens (median 13.3% in slower-growing cultures versus 2.05% in faster-growing cultures), but not from nonmalignant specimens. Conclusions. The expansion of TILs for potential therapeutic use is feasible. Our findings also indicate that further examination of TILs from prostate adenocarcinomas may yield insights into mechanisms of regulation of T cells within the tumour microenvironment. Further research is required to evaluate their therapeutic potential.http://dx.doi.org/10.1155/2022/6499344
spellingShingle Linh T. Nguyen
Charlotte S. Lo
Michael Fyrsta
Jessica Nie
Jennifer Y. Yam
Pei-Hua Yen
Michael X. Le
Karen Hersey
Miran Kenk
Megan Crumbaker
Neil Fleshner
Girish Kulkarni
Robert Hamilton
Michael Jewett
Antonio Finelli
Andrew Evans
Joan Sweet
Pamela S. Ohashi
Anthony M. Joshua
Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue
Prostate Cancer
title Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue
title_full Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue
title_fullStr Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue
title_full_unstemmed Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue
title_short Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue
title_sort expansion of lymphocytes from prostatic adenocarcinoma and adjacent nonmalignant tissue
url http://dx.doi.org/10.1155/2022/6499344
work_keys_str_mv AT linhtnguyen expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT charlotteslo expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT michaelfyrsta expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT jessicanie expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT jenniferyyam expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT peihuayen expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT michaelxle expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT karenhersey expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT mirankenk expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT megancrumbaker expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT neilfleshner expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT girishkulkarni expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT roberthamilton expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT michaeljewett expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT antoniofinelli expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT andrewevans expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT joansweet expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT pamelasohashi expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue
AT anthonymjoshua expansionoflymphocytesfromprostaticadenocarcinomaandadjacentnonmalignanttissue